This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameFiacitabine
Accession NumberDB12901
TypeSmall Molecule
GroupsInvestigational
Description

Fiacitabine has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII4058H365ZB
CAS number69123-90-6
WeightAverage: 371.107
Monoisotopic: 370.97783
Chemical FormulaC9H11FIN3O4
InChI KeyGIMSJJHKKXRFGV-BYPJNBLXSA-N
InChI
InChI=1S/C9H11FIN3O4/c10-5-6(16)4(2-15)18-8(5)14-1-3(11)7(12)13-9(14)17/h1,4-6,8,15-16H,2H2,(H2,12,13,17)/t4-,5+,6-,8-/m1/s1
IUPAC Name
1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-imino-5-iodo-1,4-dihydropyrimidin-2-ol
SMILES
[H][[email protected]]1(CO)O[[email protected]@]([H])(N2C=C(I)C(=N)N=C2O)[[email protected]@]([H])(F)[[email protected]]1([H])O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fiacitabine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Fiacitabine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fiacitabine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fiacitabine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fiacitabine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fiacitabine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Fiacitabine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fiacitabine.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Fiacitabine.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Fiacitabine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fiacitabine.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fiacitabine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.468 mg/mLALOGPS
logP0.25ALOGPS
logP0.057ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)5.22ChemAxon
pKa (Strongest Basic)0.89ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area109.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.61 m3·mol-1ChemAxon
Polarizability27.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPyrimidine nucleosides
Sub ClassPyrimidine 2'-deoxyribonucleosides
Direct ParentPyrimidine 2'-deoxyribonucleosides
Alternative ParentsAminopyrimidines and derivatives / Pyrimidones / Halopyrimidines / Primary aromatic amines / Aryl iodides / Hydropyrimidines / Imidolactams / Oxolanes / Heteroaromatic compounds / Secondary alcohols
SubstituentsPyrimidine 2'-deoxyribonucleoside / Aminopyrimidine / Halopyrimidine / Pyrimidone / Aryl halide / Aryl iodide / Hydropyrimidine / Primary aromatic amine / Pyrimidine / Imidolactam
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 19:08 / Updated on September 01, 2017 12:26